Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
25 Results for "
Heme binding
" in MedChemExpress (MCE) Product Catalog:
Products (25)
25 Results for "Heme binding" in MCE Product Catalog:
15
15 Publications Verification
Cat. No.: HY-B0754A
CAS No.: 17696-69-4
Synonyms: Hematoporphyrin IX dihydrochloride
Target:
4
4
Research Areas:
Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia) .
1
1 Cited Publications
Cat. No.: HY-B0754
CAS No.: 14459-29-1
Synonyms: Hematoporphyrin IX
Target:
Cat. No.: HY-NP007
CAS No.: 100684-32-0
Cat. No.: HY-W996116
CAS No.: 1933460-23-1
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC50=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis .
Cat. No.: HY-P2995B
Cat. No.: HY-177784
Research Areas:
iDeg-3 is a selective molecular glue degrader that targets IDO1. iDeg-3 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 46 nM). iDeg-3 can be used for the researches of cancer, infection and neurological disease, such as melanoma .
Cat. No.: HY-170322
Research Areas:
TDO2-IN-1 is a selective TDO2 inhibitor. TDO2-IN-1 binds to the active pocket, heme-binding pocket and substrate-binding pocket of apo-TDO2, interacts with key residues, competitively inhibits heme insertion, and suppresses intracellular TDO2 activity. TDO2-IN-1 can be used in research related to cancer, metabolism and other fields .
Cat. No.: HY-P4793
CAS No.: 946571-77-3
Target:
Research Areas:
Cat. No.: HY-178011
CAS No.: 1219296-74-8
Research Areas:
IDO1-IN-28 (Compound MQ-1) is a Apo-IDO1 inhibitor with an IC50 of 1.29 μM. IDO1-IN-28 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-28 can be used for cancers research .
Cat. No.: HY-178024
CAS No.: 1219340-38-1
Research Areas:
IDO1-IN-29 (Compound MQ-1n) is a Apo-IDO1 inhibitor with an IC50 of 0.29 μM. IDO1-IN-29 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-29 can be used for cancers research .
Cat. No.: HY-177785
Research Areas:
iDeg-6 is a selective molecular glue degrader that targets IDO1 with a DC50 of 6.5 nM. iDeg-6 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 1.6 μM). iDeg-6 can be used for the researches of cancer, infection and neurological disease, such as melanoma .
Cat. No.: HY-P2995C
Cat. No.: HY-P2995E
Cat. No.: HY-181947
Research Areas:
IDO1-IN-33 (Compound YC-16) is a IDO1 inhibitor (with an IC50 of 0.18 μM for IDO1 in HeLa cells). IDO1-IN-33 acts as an apo-IDO1 inhibitor by slowly and competitively displacing heme from mature holo-IDO1 and rapidly binding to the heme-binding site of immature apo-IDO1, without altering the expression level of IDO1. IDO1-IN-33 can be used for the research of hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, and cervical cancer .
Cat. No.: HY-179524
CAS No.: 332874-88-1
Research Areas:
ISR activator 2 is a selective ISR activator. ISR activator 2 can preferentially activate the ISR through the binding of the cytosolic pattern recognition receptor RIG-I, which subsequently activates the heme-regulated inhibitor (HRI) ISR kinase independent of an interferon response. ISR activator 2 can be used for the study of pancreatic cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
